Exercise alters the IGF axis in vivo and increases p53 protein in prostate tumor cells in vitro

Journal of Applied Physiology

Volumn 96, Issue 2, 2004, Pages 450-454

  Leung, Pak Shan ^a   Aronson, William J ^a   Ngo, Tung H ^a   Golding, Lawrence A ^b   Barnard, R James ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NEVADA   (United States)

Author keywords

Apoptosis; Cell growth; LN 56 cells; LNCaP cells; Proliferating cell nuclear antigen

Indexed keywords

CYCLINE; PROTEIN P53; SOMATOMEDIN;

ADULT; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; EXERCISE; GENE FUNCTION; HUMAN; HUMAN CELL; MALE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SECRETION; SERUM; TUMOR CELL LINE; UNITED STATES;

APOPTOSIS; BLOOD PROTEINS; CELL DIVISION; EXERCISE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0942276824     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/japplphysiol.00871.2003     Document Type: Article

References (43)

1. Barnard RJ, Ngo TH, Leung PS, Aronson WJ, and Golding LA. A low-fat diet and/or strenuous exercise alters the IGF axis in vivo and reduces prostate tumor cell growth in vitro. Prostate 56: 201-206, 2003.
2. Barnard RJ, Roberts CK, Varon SM, and Berger JJ. Diet-induced insulin resistance precedes other aspects of the metabolic syndrome. J Appl Physiol 84: 1311-1315, 1998.
3. Barnard RJ, Ugianskis EJ, Martin DA, and Inkeles SB. Role of diet and exercise in the management of hyperinsulinemia and associated atherosclerotic risk factors. Am J Cardiol 69: 440-444, 1992.
4. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, and Tulinius H. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 20: 680-688, 1977.
5. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, and Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566, 1998.
6. Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF Jr, and Hsing AW. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 10: 421-427, 2001.
7. Cohen P, Peehl DM, and Rosenfeld RG. The IGF axis in the prostate. Horm Metab Res 26: 81-84, 1994.
8. Evenson KR, Stevens J, Cai J, Thomas R, and Thomas O. The effect of cardiorespiratory fitness and obesity on cancer mortality in women and men. Med Sci Sports Exerc 35: 270-277, 2003.
9. Golding L. Exercise and aging: a 20-year study. In: Physical Fitness and Health Promotion in Active Aging, edited by Shiraki K, Sagawa S, and Yousef MK. Leiden, The Netherlands: Backhuys, 2001, p. 43-59.
10. Goodyear LJ and Kahn BB. Exercise, glucose transport, and insulin sensitivity. Annu Rev Med 49: 235-261, 1998.
11. Gurumurthy S, Vasudevan KM, and Rangnekar VM. Regulation of apoptosis in prostate cancer. Cancer Metastasis Rev 20: 225-243, 2001.
12. Haenszel W and Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 40: 43-68, 1968.
13. Harman SM, Metter EJ, Blackman MR, Landis PK, and Carter HB. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 85: 4258-4265, 2000.
14. Heron-Milhavet L and LeRoith D. Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage. J Biol Chem 277: 15600-15606, 2002.
15. Hsing AW, Chua S Jr, Gao YT, Gentzschein E, Chang L, Deng J, and Stanczyk FZ. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 93: 783-789, 2001.
16. Hsing AW, Gao YT, Chua S Jr, Deng J, and Stanczyk FZ. Insulin resistance and prostate cancer risk. J Natl Cancer Inst 95: 67-71, 2003.
17. Jemal A, Thomas A, Murray T, and Thun M. Cancer statistics, 2002. CA Cancer J Clin 52: 23-47, 2002.
18. Jiang X and Wang X. Cytochrome c promotes caspase-9 activation by inducing nucleotide binding to Apaf-1. J Biol Chem 275: 31199-31203, 2000.
19. Jonsson F, Wolk A, Pedersen NL, Lichtenstein P, Terry P, Ahlbom A, and Feychting M. Obesity and hormone-dependent tumors: cohort and co-twin control studies based on the Swedish Twin Registry. Int J Cancer 106: 594-599, 2003.
20. Leri A, Liu Y, Claudio PP, Kajstura J, Wang X, Wang S, Kang P, Malhotra A, and Anversa P. Insulin-like growth factor-1 induces Mdm2 and down-regulates p53, attenuating the myocyte renin-angiotensin system and stretch-mediated apoptosis. Am J Pathol 154: 567-580, 1999.
21. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, and Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76: 1115-1118, 1997.
22. Ngo TH, Barnard RJ, Leung PS, Cohen P, and Aronson WJ. Insulin-like growth factor I (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: possible mediators for the effects of diet and exercise on cancer cell survival. Endocrinology 144: 2319-2324, 2003.
23. Ngo TH, Barnard RJ, Tymchuk CN, Cohen P, and Aronson WJ. Effect of diet and exercise on serum insulin, IGF-I, and IGFBP-1 levels and growth of LNCaP cells in vitro. Cancer Causes Control 13: 929-935, 2002.
24. Ossovskaya VS, Mazo IA, Chernov MV, Chernova OB, Strezoska Z, Kondratov R, Stark GR, Chumakov PM, and Gudkov AV. Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains. Proc Natl Acad Sci USA 93: 10309-10314, 1996.
25. Parrizas M and LeRoith D. Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinology 138: 1355-1358, 1997.
26. Pasquali R, Casimirri F, De Iasio R, Mesini P, Boschi S, Chierici R, Flamia R, Biscotti M, and Vicennati V. Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men. J Clin Endocrinol Metab 80: 654-658, 1995.
27. Plymate SR, Matej LA, Jones RE, and Friedl KE. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 67: 460-464, 1988.
28. Riss TL and Moravec RA. Comparison of MTT, XTT, and a novel tetrazolium compound for MTS for in vitro proliferation and chemosensitivity assays (Abstract). Mol Biol Cell 3. Suppl: 184a, 1992.
29. Rokhlin OW, Gudkov AV, Kwek S, Glover RA, Gewies AS, and Cohen MB. p53 is involved in tumor necrosis factor-alpha-induced apoptosis in the human prostatic carcinoma cell line LNCaP. Oncogene 19: 1959-1968, 2000.
30. Severson RK, Nomura AM, Grove JS, and Stemmermann GN. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res 49: 1857-1860, 1989.
31. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, and Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 63: 963-966, 1991.
32. Singh MA, Ding W, Manfredi TJ, Solares GS, O'Neill EF, Clements KM, Ryan ND, Kehayias JJ, Fielding RA, and Evans WJ. Insulin-like growth factor I in skeletal muscle after weight-lifting exercise in frail elders. Am J Physiol Endocrinol Metab 277: E135-E143, 1999.
33. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, and Kaaks R. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 92: 1910-1917, 2000.
34. Tada H, Shiho O, Kuroshima K, Koyama M, and Tsukamoto K. An improved colorimetric assay for interleukin 2. J Immunol Methods 93: 157-165, 1986.
35. Takahashi K and Suzuki K. Association of insulin-like growth-factor-I-induced DNA synthesis with phosphorylation and nuclear exclusion of p53 in human breast cancer MCF-7 cells. Int J Cancer 55: 453-458, 1993.
36. Thomas DB and Karagas MR. Cancer in first and second generation Americans. Cancer Res 47: 5771-5776, 1987.
37. Thune I and Furberg AS. Physical activity and cancer risk: dose-response and cancer, all sites and site-specific. Med Sci Sports Exerc 33, Suppl: S530-S550 and S609-S610, 2001.
38. Tymchuk CN, Barnard RJ, Heber D, and Aronson WJ. Evidence of an inhibitory effect of diet and exercise on prostate cancer cell growth. J Urol 166: 1185-1189, 2001.
39. Tymchuk CN, Barnard RJ, Ngo TH, and Aronson WJ. Role of testosterone, estradiol, and insulin in diet- and exercise-induced reductions in serum-stimulated prostate cancer cell growth in vitro. Nutr Cancer 42: 112-116, 2002.
40. Tymchuk CN, Tessler SB, Aronson WJ, and Barnard RJ. Effects of diet and exercise on insulin, sex hormone-binding globulin, and prostate-specific antigen. Nutr Cancer 31: 127-131, 1998.
41. Vairapandi M, Balliet AG, Fornace AJ, Hoffman B, and Liebermann DA. The differentiation primary response gene MyD118, related to GADD45, encodes for a nuclear protein which interacts with PCNA and p21WAF1/CIP1. Oncogene 12: 2579-2594, 1996.
42. Wahl GM and Carr AM. The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat Cell Biol 3: E277-E286, 2001.
43. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, and Trichopoulos D. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 90: 911-915, 1998.